Abstract
This article outlines the link between the renin angiotensin aldosterone system (RAAS) and various forms of cardiomyopathy, and also reviews the understanding of the effectiveness of RAAS intervention in this phase of ventricular dysfunction. The authors focus their discussion predominantly on patients who have had previous myocardial infarction or those who have left ventricular hypertrophy and also briefly discuss the role of RAAS activation and intervention in patients with alcoholic cardiomyopathy.
Copyright © 2012 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiotensin II / drug effects
-
Angiotensin II / physiology
-
Angiotensin-Converting Enzyme Inhibitors / administration & dosage
-
Angiotensin-Converting Enzyme Inhibitors / pharmacology
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Animals
-
Diabetic Angiopathies / physiopathology
-
Heart Failure / drug therapy
-
Heart Failure / etiology
-
Heart Failure / physiopathology*
-
Humans
-
Myocardial Infarction / complications
-
Myocardial Ischemia / physiopathology
-
Renin-Angiotensin System / physiology*
-
Signal Transduction / physiology
-
Stroke Volume / physiology
-
Ventricular Dysfunction, Left / physiopathology*
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Angiotensin II